Skip to search formSkip to main contentSkip to account menu

sitagliptin

Known as: Sitagliptin [Chemical/Ingredient], 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine, Sitagliptinum 
An orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may… 
National Institutes of Health

Related topics

Related topics

15 relations
24 HR Metformin hydrochloride 1000 MG / sitagliptin 50 MG Extended Release Oral Tablet24 HR Metformin hydrochloride 1000 MG / sitagliptin 50 MG Extended Release Oral Tablet [Janumet]Diabetes Mellitus, Insulin-DependentDiabetes Mellitus, Non-Insulin-Dependent

Narrower (4)

JanumetJanuviaMK 0431sitagliptin phosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
2015
2015
The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
2015
2015
The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma.
2013
2013
Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.
2013
2013
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin is an attractive therapy for diabetes, as it increases insulin release… 
2012
2012
A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent
To describe a protocol for active surveillance of acute myocardial infarction (AMI) in users of a recently approved oral… 
2012
2012
Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
(J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00221.x, 2012) 
2011
2011
Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
2010
2010
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats
The SHROB (spontaneously hypertensive rat – obese strain) is a model of prediabetes and metabolic syndrome with insulin… 
Review
2008
Review
2008
DPP4 inhibitors for diabetes--what next?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)